There is an estimated worldwide shortage of 75-90 million units of blood each year. Additionally, the time and cost involved in blood matching requirements and the threat of disease transmission creates a unique market opportunity: the development of a universal donor red blood cell substitute.
We have developed technology at University of California San Diego UCSD and patented process of producing and proliferating red blood cells from embryonic stem cells ESC in large quantities. This product is poised to become the first-in-market safe, non-toxic, widely-applicable, readily-available, cost-effective, and long-lived blood substitute. The risks of cancer normally associated with ES does not exist with CD34+ cells generation because RBC cells do not have a nucleus and thus do not have any genetic material that could be the source of cancer risk.
The founding team is comprised of the scientists and clinicians who created the IP at UCSD. The team has published research publications on the generation of blood stem cells from human ES. We have already demonstrated this capability in the lab and tested on mice. The Scientific Advisory Board includes Dr. Evan Snyder who is Program Director of Stem Cells and Regenerative Medicine at the Burnham Institute for Medical Research.
Name and contact details of Chairperson/Managing director
4 Sukruti Bunglows, Near Baghban Party Plot, Thaltej , Ahmedabad 380058
The team comprises of highly reputed researchers from USA with patent developed in US at the most reputed universities as well as experience executing successful commercialization projects at scale in US & India.